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Abstract
Stem cells seem to offer an alternative venue for treating many cell related diseases, such as age-related macular degeneration
(ARMD). ARMD is a progressive neurodegenerative medical condition, which primarily affects the retinal pigmented epithelium
(RPE), resulting in degeneration of photoreceptors. Scientists have been successful in implanting stem cells into the eyes of rats.
These injected cells sustained visual function and photoreceptor integrity without any cancerous cell formation.There are numerous treatments available to slow down the progression of ARMD. Depending on the type of ARMD, doctors may either recommend
leading a healthier lifestyle or that one should undergo surgery. Numerous risk factors can increase one’s chances of getting
ARMD depending on one’s age and race. Bad habits, such as cigarette smoking, can contribute to the progression of ARMD. It
is important to get a comprehensive dilated eye exam periodically. Many eye diseases that don’t have any warning signs can be
detected with such an eye exam.
Introduction
The most versatile cell types in the human body are embryonic
stem cells. Stem cells have three unique general properties that
distinguish them from other cells in the body. One is that these
cells can replicate themselves even after long periods of inactivity. Secondly, stem cells are unspecialized. These cells are not
programed to become any specific tissue. For example, stem
cells can’t work with other red blood cells to carry oxygen
containing molecules through the blood stream. Thirdly, under
certain physiologic or experimental conditions, stem cells can
become the specialized cells that make up tissues and organs
(National Institutes of Health 2016).
When stem cells divide, they can make either more stem cells,
or can differentiate into a specialized cell which is tasked with
a specific function. For example, these stem cells can turn into
motoneurons which are used for motor skill or into cardiomyocytes to help pump blood through the arteries. However,
Adult stem cells can only generate cells that are like the tissue
in which they are located in (Tuch, 2006). For example, hematopoietic stem cells in the bone marrow form only cells that give
rise to the different types of blood cells and cannot make nerve
cells for the brain.
Embryonic stem cells are made from oocytes that have been
fertilized in vitro and not in a women’s body. The process of
priming the cells in an in vitro fertilization clinic is known as cell
culture. Human embryonic stem cells are primed by placing an
embryo into a culture dish that contains a culture medium.With
the right physiological conditions, these cells begin to divide
and spread over the surface of the dish forming millions of unspecialized stem cells. Although scientists have not agreed upon
a battery of tests to ensure they are growing only unspecialized
cells, there are some common tests performed to determine
the cells fundamental properties. One technique used is by
looking for particular cell surface markers, such as transcription
factors, that are generally produced by undifferentiated cells.
Stem cells in their culture dish can remain undifferentiated
as long as they are under the appropriate conditions. However,
cells automatically begin to differentiate once they are allowed
to cluster together to form embryoid bodies. These cells can
then begin to form tissue specific cells, such as muscle or nerve

cells. Although differentiation is a sign of a healthy culture, this
process is generally uncontrolled, and therefore an inefficient
way to produce specialized cells. In order to create a more controlled experiment, scientists change around the chemical composition of the culture medium or by inserting specific genes to
specialize the cells in an organized fashion.
Human embryonic stem cells have many applications in clinical use and in research. One useful application is in cell-based
therapies, situations where stem cells are induced to turn into
specialized cells. Through this process, new cells which are
needed to repair destroyed tissue can be formed. For example, these specialized cells can replace bone marrow, muscle,
and brain cells that are injured or malfunctioning. These cells
form an internal repair system by cell mitosis for as long as the
organism is alive. Due to their ability to replace damaged cells,
stem cells seem to offer an alternative venue for treating many
cell related diseases as well. If scientists can reliably find a way
to differentiate the cells in an organized manner, then they may
be able to cure many diseases in the future (Weiss,Troyer, 2006).
One of the diseases that scientists believe embryonic stem
cells can treat is age related macular degeneration (ARMD)
(Shroff, 2015). Over 10 million Americans have vision loss related to Macular degeneration. Macular degeneration is the
third most common pathological condition leading to vision
impairment (Resnikoff, et. al., 2004). ARMD is a progressive neurodegenerative medical condition, which primarily affects the
retinal pigmented epithelium (RPE), resulting in degeneration
of photoreceptors. This causes loss of vision in the center of
the field of vision. The disease is caused by the deterioration of
the macula, a region that is located at the center of the retina
and is responsible for focusing central vision in the eye. This
allows people to ride their bike or recognize a familiar face.
Common symptoms include not being able to see in dim light,
seeing spots, and distorted vision.
There are two types of ARMD. There is the wet as well as
the dry form. Most of the cases of ARMD are the dry form.
Dry ARMD is also known as non-neovascular ARMD as well
as non-exudative ARMD since there areno fluids that leak into
the macula from blood vessels. Although people with this form
of ARMD may have fair central vision of at least 20/40, they
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may have other functional limitations, such as fluctuating vision,
poor night vision, and pixelated vision. In this form of ARMD,
the deterioration by the macula is linked with the appearance
of drusen. Drusen are small yellow deposits that form under
the macula. These deposits are buildups of shapeless acellular
debris from the basement membrane of the RPE. This buildup
of drusen causes the macula to thin and dry out, thereby causing
the macula to lose its function.This process is known as atrophy.
The amount of vision loss that occurs is directly proportional
to the amount as well as the location of the drusen. Advanced
cases of dry ARMD are also known as geographic atrophy (GA)
since large areas of the retina stop functioning. Patients with GA
usually see large blank spots in their central vision because their
macula has deteriorated. Usually, most people over 50 years old
have a drusen buildup in at least one of their eyes. Currently,
there is no known cure for this form of the disease.
However, some cases of dry ARMD progress into the wet
form. In the wet form, there is an abnormal blood vessel growth
under the macula. This type of growth is known as choroidal
neovascularization (CNV). Once CNV has occurred in one eye,
the patient has a higher risk that the other eye will get CNV
as well. These new blood vessels are generally weak and can
rupture easily.When they rupture, they leak fluids, such as blood
and lipid containing solutions. This causes the macula to bulge,
thereby causing a distorted central vision. These conditions can
cause severe vision loss in a short amount of time. In this form
of ARMD, patients may see spots because of the fluid buildup
under the macula. Therefore, periodic eye exams are vital, especially if the patient is at a higher risk of contracting ARMD.
There are three stages in ARMD. There is early, intermediate,
and late stage ARMD. During early stage, most people don’t realize any of the symptoms. Therefore, it is crucial to have regular
eye exams. Early ARMD is diagnosed by the appearance of drusen
the size of 63 microns by the macula. In the intermediate ARMD,
there may be some vison blur in the central vision and by late
ARMD there is a noticeable vision loss in the central vision.
Medical experts aren’t exactly sure what causes ARMD but
once present, many factors contribute to its progression. A person’s age is by far the biggest factor for ARMD. Once one turns 50,
they should visit an optometrist for a comprehensive dilated eye
exam. Many eye diseases that don’t have any warning signs can be
detected with such an eye exam.This exam includes a visual acuity
test, a visual field test, dilation, and tonometry. Annual exams are
recommended once a year once one turns 60. However, if one
is African American, then they should get one when they turn 40
since they have a higher risk for glaucoma. Although there aren’t
any cures presently available, there are numerous treatments t for
ARMD. Many doctors may prescribe a strict diet and exercise to
slow down the progression. However, none of them can cure the
disease, except potentially stem cells.
Although stem cells may offer new therapies, their use has
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been very controversial. People oppose stem cell research since
one is harvesting a fertilized egg. They believe that this is wrong
since this is tantamount to killing an unborn child, and therefore
one should respect the value of a human life. However, others
feel that morally it’s our duty to prevent or alleviate a person
from suffering.

Methods
Literature for this article was obtained primarily using Touro
College’s Online library. Other databases, such as PubMed, were
used. Additionally, Google Scholar was valuable for finding necessary and relevant articles.

Discussion
The retina of the eye is tasked with converting light into vision.At
the center of the retina is the macula. In the retina, there are the
rods and cones which process light into nerve impulses. Behind
the photoreceptor layer is the retinal pigmented epithelium (RPE).
The RPE is tasked with delivering nutrients and removing wastes
from the photoreceptor cells. In ARMD, RPE stops functioning,
causing the cones and rods to deteriorate. Today, scientists are
using stem cell research to understand how diverse cells in the
retina interact with one another. This has led to discovering new
ways of replacing photoreceptors and the underlying RPE.
Generally, replacing dead cells with stem cells is very challenging since the stem cells would have to establish new connections
with the surrounding nerve fibers that ultimately relay the message to the brain. However, the eye is a great target for stem cell
research since there are many barriers in the eye, such as tight
cell junctions, therefore making it relatively self-contained. This
prevents the migration of cells outside of the eye. Furthermore,
with the use of an ophthalmoscope it is easy to assess the effectiveness of the treatments. Doctors can also compare the
treated eye with the other eye to evaluate the effectiveness of
the treatments.
RPE cells are easier to integrate with existing retinal cells since
they don’t need to connect with nerve fibers. With stem cells
research, one can use new RPE cells to replace dead RPE cells.
If the stem cells are replaced before the photoreceptors have
completely deteriorated, then the new RPE cells may be able to
prevent existing photoreceptors from dying, thereby preventing
the progression of the disease. Stem cells can also be used to
discover new therapies. When damaged RPE cells are stressed,
they produce characteristics of ARMD. These damaged cells can
then be studied to evaluate the different surface markers present which can help in early intervention and in getting a better
diagnosis.
Scientists have come up with different methods to replace the
RPE layer. One method is using human embryonic stem cells.
These cells are naturally pluripotent when harvested and can
renew for long periods if properly maintained in vitro. They can
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transform into the ectoderm, endoderm, and mesoderm. These
three primary germ layers can differentiate into all the cells in
the body. However, there are numerous obstacles raised with
this method. One of the problems is whether it is ethical to
harvest embryos since they can turn into a fetus (Narsinh, et. al.,
2011). Another challenge that must be overcome is the limited
supply of human embryo donors.
Another method researchers have used is induced pluripotent stem cells
(hiPSCs).These are usually epithelial cells that are reprogramed
to behave like embryonic stem cells. They can then be used to
grow rods and cones or RPE cells. The landmark discovery of
hiPSCs has been hailed as a significant advance in stem cell research. This method circumvents the ethical debate with embryonic stem cells since no human embryo is destroyed ex utero.
However, there are numerous problems with this method as well.
Extensive research has shown that these cultures cells can turn
into benign or malignant tumors (Ho, et. al., 2012). Therefore,
these issues preclude clinical use of these cells for now.
Another method which scientists are experimenting with is
adult stem cells. This method entails growing RPE specific stem
cells from adult stem cells. One source for such cells is from
eyes donated to eye banks. These cells are less likely to be rejected if used in implants. However, there usually is a limited
amount in each tissue, therefore making it harder to find and
purify. Furthermore, these cells can’t be stored for any length of
time before they turn cancerous (Reya, et. al., 2001).

Delivery Method for Stem Cells
Although there are no FDA approved cures for ARMD, implantation of healthy RPE into the macula may prove to be an effective
treatment.The following procedure was used to deliver RPE into
rats. After the rat was put under a general anesthetic, a hole was
created in the eye using a sharp needle. Then, a blunt needle was
inserted into the hole until it reached the RPE layer, into which
the stem cells were injected (Westenskow, et. al., 2015).
In one study, animal models, such as rats and mice with
macular degeneration, were treated with stem cells that become RPE cells (Lu, et. al., 2009). To simulate real life conditions, the rats were under a 12-hour light /dark cycle. One
day prior to their transplantation, all animals in the main experiment were administered cyclosporine to prevent organ
rejection. Before the researchers administered the cells, they
washed the cells in balance salt solution. Two weeks after the
transplantation, the rats received an intraperitoneal injection
of dexamethasone. This steroid was injected to treat the resulting inflammation.
These injected cells sustained visual function and photoreceptor integrity without any cancerous cell formation. Visual
acuity increased when the models received a dose between
5000-100,000 RPE cells. Following the procedure, the rats were

monitored to check for any adverse reaction. They found that
visual function was sustained for at least two months. The cells
themselves survived for at least half a year before they started
to deteriorate. However, this deterioration in visual acuity can
be due to insufficient cyclosporine. Another hypothesis of why
the cells deteriorated can be because the transplantation may
need to be repeated several times in order to sustain their therapeutic effect.

ARMD Treatments
For early dry ARMD, doctors recommend a diet that is high
in antioxidants, such as strawberries and oranges. However, if
the patient has an advanced stage of dry ARMD, such as GA,
then the doctor may prescribe supplements that increase vital
vitamins that support the cell.
Until recently, the only treatment for wet ARMD was laser
photocoagulation. This treatment by an ophthalmologist is a
minimally invasive procedure which uses a laser to burn and
destroy leaking blood vessels. However, this treatment cannot
restore vision that has been lost already. One drawback to
their use is that most CNV lesions are too big to be treated
by laser coagulation. Another is that there is a high chance that
the leakage will reoccur over time. Because of these limitations,
scientists have been looking for alternative therapies that are
safe and effective for a long period of time.
One alternative treatment that is widely used today is Antivascular endothelial growth factor (VEGF) therapy. This therapy includes periodic intraocular injections of a chemical called
anti-VEGF. Normally, VEGF is beneficial for the circulatory system since it helps promote the growth of new blood vessels.
However, having too much by the macula can have deleterious
effects on it since they promote the growth of weak new blood
vessels. This intravitreal shot of anti VEGF stops the development of new blood vessels by the macula, thereby preventing
any further leaks. However, there are numerous side effects
with this treatment. Patients have complained about vitreous
floaters. This happens since the doctor punctures the vitreous
layer of the eye. Another side effect observed was an elevated
eye pressure. This can cause glaucoma if left untreated.

Human Implant
Although stem cells have been proposed as a potential treatment in treating ARMD, there are still numerous drawbacks to
their use. Safety concerns have been raised since there is a risk
that these cells may turn into unwanted cell types which can lead
to tumor formation in the eye and potential immune rejection.
Although stem cells were discovered in the late 1990s, scientists
did not know how to find a safe way of implanting them. The
first reported transplanted hESC-derived cells into the macula
was in 2012. hESC-derived retinal pigment epithelium cells were
transplanted into the subretinal portion of the of the eyes of
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dry ARMD patients (Schwartz, et. al., 2012). Ninety-nine percent
of the stem cells differentiated into RPE cells. These differentiated cells integrated into the host forming a homogenous RPE
layer. Post-surgery, structural evidence showed that the cells had
attached and continued to persist during the study. During the
first four months, there were no signs of hyperproliferation, cell
rejection, or abnormal growth.
The scientists didn’t find any signs of adverse proliferation or
any other type of ocular disease. This method proved to be a
safer method for treating ARMD than other conventional methods, such as vitreoretinal surgery and immunosuppression. The
results of this study provide the first evidence for medium to
long term safety as well as graft efficacy.These results suggest that
stem cells can be a safe alternative for many medical diseases that
require tissue replacement. Therapeutic goals for the future will
be to treat the patient in the earlier stages of macular degeneration, thereby preventing the photoreceptors from decaying.

Risk Factor
A study was conducted to evaluate the effects of antioxidants
on AMRD. In this clinical experiment, they enrolled 3,640 participants who showed signs of ARMD.These participants had drusen
buildup in at least one of their retinas. The size of drusen buildup was between 63-150 microns. Participants were randomly
assigned supplements that contained either 500 mg L-ascorbic
acid, 400 IU tocopherols, or a placebo. The researchers found
that compared to the placebo a high dose of L-ascorbic acid
and various tocopherols may delay the progression of ARMD
and other forms of vision loss. These supplements showed no
adverse effects, proving their safety (Age-Related Eye Disease
Study Research Group, 2001).
A study was conducted to assess the risk of smoking in men.
This study consisted of 21,157 US male physicians who did not
have any known diagnosis of ARMD. Of them, 11% were current
smokers, 39% were past smokers, and 50% that never smoked.
Over the course of 12 years, they found 268 incidents of ARMD.
Current smokers who smoked a pack a day had a 240 percent
risk increase compared to nonsmokers. Past smokers had a 30
percent increased risk of contracting ARMD. Current smokers
who smoke less than 20 cigarettes had only a modest risk increase of 26 percent (Christen, et. al., 1996). Unlike other risk
factors, such as age, smoking is an avoidable risk factor.
Since there aren’t any cures that are reliable for ARMD, it is
therefore recommended to avoid smoking altogether. However,
it could be that the study on smoking isn’t 100 percent accurate.
It could be that the subjects who didn’t smoke had a slower
progression since they ate foods rich in omega-3 fatty acid. This
acid can be found in many common household products, such
as fish and canola oil. In a study conducted with 681 twins, they
found that having 2 or more servings of fish reduced the risk of
ARMD by 45 percent (Seddon, et. al., 2006).
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Although some fruits and vegetables can slow down the progression of ARMD, such as those rich in L-ascorbic acid and
tocopherols, other vegetables can be bad for ARMD. One study
tried to find out if dietary nitrates can increase your chance
of getting ARMD. These nitrates can be found in leafy vegetables, such as lettuce and spinach. In this study, there were 2,856
participants.The scientists took numerous potential cofounders
into account such as age, sex, smoking, energy intake, and fish
consumption. The participants were monitored for 15 years.
The scientists found that those who had a dietary nitrate intake
had a 39 percent increase incidence of having ARMD (Gopinath,
et. al., 2018). However, this percentage increase cannot be said
to apply for all ethnic groups.
A prospective cohort study of 6,176 participants between
the ages of 45 to 85 was used to find the prevalence of ARMD
between four racial groups. These groups were white, black,
Hispanic, and Chinese. The method they used to test for ARMD
was by taking a picture of the fundus through the dark-adapted
pupils, whereupon they were able to measure the drusen size.
What they found is that Hispanics had a 1.8 percent increase
in prevalence compared to the black ethnic group. The Chinese
had a 2.2 percent increase, and the white had a 3 percent increase compared to the blacks. Differences in age, gender,
pupil size, body mass index, smoking, alcohol drinking history,
diabetes, and hypertension status did not explain the variability
among the 4 racial/ethnic groups (Klein, et. al., 2006).
A person’s age is by far the biggest factor for ARMD. In a
population-based study, scientists tried to find the prevalence
of ARMD in a sample of Hispanic individuals over the age of
50. All 4,774 participants had an initial ophthalmic evaluation to
determine a baseline for comparison. Over the course of the
study, the scientists monitored drusen size, drusen type, and
the area covered by drusen. They found that the prevalence of
early and late ARMD increased with age.The prevalence of early
ARMD varied with age as follows: people between 50 and 60
had a 20 percent increase, while those aged 80 and older had a
54 percent increase. The prevalence of late ARMD varied with
age as well. Those in the age group of 50 to 60 had a .1 percent
increase, while those 80 years and older had a 4.3 percent increase (Muñoz, et. al., 2005).

Conclusion
Currently, there is no FDA approved cure for ARMD. However,
one promising cure currently being researched is stem cell
transplantation. However, there are numerous obstacles that
still need to be overcome before they can be safely implanted
into patients. Depending on the type of ARMD, doctors may either recommend leading a healthier lifestyle or that one should
undergo surgery. As one ages, one is more prone to getting
ARMD.Therefore, it is important to get a comprehensive dilated
eye exam periodically.
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